Mast Therapeutics, Inc. (NYSEMKT:MSTX) registered a 0.00% increase, still its new closing price is 88.57% up from the company’s 1 year high of 0.71.It posted 2.25% gains in previous 5 sessions and is now the subject of 1 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 0 buy or better ratings. The 3 stock analysts following this company have an average price target at $2.50, with individual PT in the $2.50-$2.50 range. The shares moved at $0.13, implying that brokerage firms see shares losing about -67.00% in twelve months time.

Mast Therapeutics, Inc. (MSTX) SEC Form 4 News

The stock is getting much attention these days as insiders are adding shares while they posted a 46.67% rise year to date. A CFO & SVP at Mast Therapeutics, Inc. (MSTX) acquired shares in a transaction closed on Friday March 27, 2015. Roberts Brandi bought 256,000 shares in the company at $0.5 each and collected $19,000 in proceeds. Roberts Brandi now owns 38,000 shares in the company after this transaction.

Mast Therapeutics, Inc. (NYSEMKT:MSTX) Upcoming Results on Tap

Mast Therapeutics, Inc. will next provide financial results for the December 2017 quarter. Stock analysts expect it to report per-share earnings of $0.27 in that period. Sales during the quarter are predicted to arrive at $0.

Earnings surprise history: Last quarter, the company posted approximately $0 in revenue and EPS of $-0.04. The mean forecast was for $0 and $-0.05 a share, respectively. One quarter earlier, revenue for the stock was at $0, with earnings at $-0.05/share.

Mast Therapeutics, Inc. (MSTX) Brokerage Update 

Mast Therapeutics, Inc. (MSTX) is in Maxim Group’s research list so their analyst rating change is noteworthy. These shares were downgraded to Hold from Buy by Maxim Group, according to news reported on Wednesday September 21, 2016. Over the last six months and over the last three months, the shares of Mast Therapeutics, Inc. (MSTX), have changed -63.33% and 65.00%, respectively.